Connect with us

Bloomberg Technology

Sorrento’s Covid-19 Antibody in Question

May.22 — Sorrento Therapeutics recently said its antibody cocktail has shown 100% inhibition of Covid-19 virus infection, but critics have begun to question its efficacy. Dr. Henry Ji, chairman and chief executive officer at Sorrento Therapeutics, discusses on “Bloomberg Technology.”

Published

on

May.22 — Sorrento Therapeutics recently said its antibody cocktail has shown 100% inhibition of Covid-19 virus infection, but critics have begun to question its efficacy. Dr. Henry Ji, chairman and chief executive officer at Sorrento Therapeutics, discusses on “Bloomberg Technology.”

Continue Reading
Advertisement
25 Comments

25 Comments

  1. Xu Caesar

    May 22, 2020 at 11:51 pm

    CCP Spy!Pay attention!!They want to stole vaccine!!

    • Shaun

      May 23, 2020 at 12:13 am

      Xu Caesar With the whole f—king world trying to come up with a vaccine together, why would the US be hiding their own? For monopoly?

    • Eco Builder

      May 23, 2020 at 7:41 am

      Too late China announced the CURE last night … same thing as DR Henry of SRNE. China tested on humans while FDA is sleeping and not approving Dr henry to move ahead

  2. Fire

    May 23, 2020 at 1:49 am

    pump and dump DONT BUY !!!!

    • DoubleHarmony

      May 23, 2020 at 3:07 am

      Short and Distort don’t fall for it

    • Eco Builder

      May 23, 2020 at 7:39 am

      BUY BUY BUY … China just made the announcement cure found tested on humans. exactly the same thing

  3. Fire

    May 23, 2020 at 1:49 am

    HENRY JI IS A FAILURE !!!!!!

    • DoubleHarmony

      May 23, 2020 at 3:05 am

      Short and Distort attempt, don’t listen to these fools.

    • Eco Builder

      May 23, 2020 at 7:40 am

      AMERICA is first to discover and announce a cure. We are proud of Dr Henry

    • Fire

      May 23, 2020 at 8:49 am

      @Eco Builder he said he doesnt have cure he has antibody LMFAO. he lied !!!!

  4. BasundhiBiryani

    May 23, 2020 at 2:09 am

    It’s just a concept/theory they have, no cure found. Manipulated stock, should be delisted

    • Eco Builder

      May 23, 2020 at 7:37 am

      Listen careful. If you are just infected, you can be cured within 4 days. It can also use as preventive antidode
      But not like vaccine to cure those already suffering from infection long period

  5. Joe Bloe

    May 23, 2020 at 5:42 am

    Good — no Emily Chang!! Taylor is a much better host!

  6. Sadak Vali Syed Vajrakarur

    May 23, 2020 at 6:35 am

    It is pump and dump company I have lost $400 should sue this company announcing COVID19 fake antibody news into market

    • Eco Builder

      May 23, 2020 at 7:35 am

      if you lose money go screw Hindenburg … they short sell to make millions in profit on day one. Cure is real

    • Sadak Vali Syed Vajrakarur

      May 23, 2020 at 7:41 am

      @Eco Builder Not sure who are they ultimately I have lost money which I have hard earned money scooped up by this kind of news so pathetic

  7. M. D

    May 23, 2020 at 7:02 am

    People should not blame poor trading on a company lol I also bought hi but sold and bought lower minimize your risk

  8. Davian's Dad

    May 23, 2020 at 8:17 am

    Back to $10 tomorrow. 🙂

    • ahmet durmaz

      May 23, 2020 at 10:43 am

      Why that

    • Davian's Dad

      May 25, 2020 at 6:48 pm

      ahmet durmaz you didn’t see it go to $10.

  9. Art Of Money

    May 23, 2020 at 3:51 pm

    People need to understand when you invest in Biotech companies make sure you know exactly if they are in Phase 1, Phase 2 or 3. Phase 1 news is only a reaction play for a quick trade. The final product could take months and is for long holders. Pick your time frame and trade it accordingly!

    • thu vu

      May 24, 2020 at 5:32 pm

      When is the good time to invest in?

    • ahmet durmaz

      May 24, 2020 at 6:56 pm

      @thu vu buy now or regret it later

  10. Ajaypal Singh

    May 24, 2020 at 3:53 pm

    People blaming company .. thts funny ???? people tell me how much money you loose when you stocks no matter what you buy. Once a blue moon you make money

  11. Shadow Gallery

    May 25, 2020 at 10:24 pm

    Watch closely. Those who are polarizing….good faith…..pulled out of Novavax for this company….

Leave a Reply

Your email address will not be published. Required fields are marked *

Bloomberg Technology

Crusoe CEO: Data Center Indusry Has a ‘Marketing Issue’

Crusoe CEO Chase Lochmiller discusses the AI infrastructure company’s nearly $4 billion in fresh funding sending its valuation to almost $31 billion. He also discusses how it will fuel the company’s push to build AI infrastructure spanning data centers, cloud computing and managed AI services. He says Crusoe could eventually enter the public markets and…

Published

on

Crusoe CEO Chase Lochmiller discusses the AI infrastructure company’s nearly $4 billion in fresh funding sending its valuation to almost $31 billion. He also discusses how it will fuel the company’s push to build AI infrastructure spanning data centers, cloud computing and managed AI services. He says Crusoe could eventually enter the public markets and pushes back against growing opposition to data centers, arguing the industry has a “marketing issue” and needs to better communicate its impact on water, jobs and local tax revenue. He joins Ed Ludlow on “Bloomberg Tech.”
——–
Like this video? Subscribe to Bloomberg Tech on YouTube:

 
Watch the latest full episodes of “Bloomberg Tech” with Ed Ludlow here:

 
Get the latest in tech from Silicon Valley and around the world here:

Connect with us on…
X:
Facebook:
Instagram:
 
Follow Ed Ludlow on X here:
 
Listen to the daily Bloomberg Tech podcast here:

 
More from Bloomberg Business
Connect with us on…
X:
Facebook:
Instagram:
LinkedIn:
TikTok:

Continue Reading

Bloomberg Technology

Former FTC Technologist Warns Against an AI ‘Cartel’

As frontier AI labs seek greater coordination on safety, Neil Chilson, Head of AI Policy at the Abundance Institute and former FTC Chief Technologist, warns that government-backed antitrust exemptions could create a durable “cartel” that ultimately harms competition. He argues companies can collaborate on safety standards without suspending antitrust rules, and that existing consumer-protection and…

Published

on

As frontier AI labs seek greater coordination on safety, Neil Chilson, Head of AI Policy at the Abundance Institute and former FTC Chief Technologist, warns that government-backed antitrust exemptions could create a durable “cartel” that ultimately harms competition. He argues companies can collaborate on safety standards without suspending antitrust rules, and that existing consumer-protection and liability laws already provide tools for addressing harms caused by AI. He joins Ed Ludlow on “Bloomberg Tech.”
——–
Like this video? Subscribe to Bloomberg Tech on YouTube:

 
Watch the latest full episodes of “Bloomberg Tech” with Ed Ludlow here:

 
Get the latest in tech from Silicon Valley and around the world here:

Connect with us on…
X:
Facebook:
Instagram:
 
Follow Ed Ludlow on X here:
 
Listen to the daily Bloomberg Tech podcast here:

 
More from Bloomberg Business
Connect with us on…
X:
Facebook:
Instagram:
LinkedIn:
TikTok:

Continue Reading

Bloomberg Technology

Anthropic Investor Franklin: AI Safety Concerns Won’t Slow Spending

Calls to “pace” development at the AI frontier are unlikely to translate into a slowdown in infrastructure spending, according to Sara Araghi, Franklin Templeton Portfolio Manager and Franklin Venture Partner. She argues that even if labs temper some model training, growing inference demand will continue to require enormous amounts of compute. Araghi also discusses why…

Published

on

Calls to “pace” development at the AI frontier are unlikely to translate into a slowdown in infrastructure spending, according to Sara Araghi, Franklin Templeton Portfolio Manager and Franklin Venture Partner. She argues that even if labs temper some model training, growing inference demand will continue to require enormous amounts of compute. Araghi also discusses why heightened AI safety concerns could boost demand for cybersecurity and why she doesn’t expect the debate to derail funding or anticipated AI IPOs. She joins Ed Ludlow on “Bloomberg Tech.”
——–
Like this video? Subscribe to Bloomberg Tech on YouTube:

 
Watch the latest full episodes of “Bloomberg Tech” with Ed Ludlow here:

 
Get the latest in tech from Silicon Valley and around the world here:

Connect with us on…
X:
Facebook:
Instagram:
 
Follow Ed Ludlow on X here:
 
Listen to the daily Bloomberg Tech podcast here:

 
More from Bloomberg Business
Connect with us on…
X:
Facebook:
Instagram:
LinkedIn:
TikTok:

Continue Reading

Trending